Familial paraganglioma syndromes

Area of Science:

• Endocrinology
• Genetics
• Oncology

Background:

• Paragangliomas and phaeochromocytomas present in syndromic and sporadic forms.
• Syndromic forms are linked to MEN2, von Hippel-Lindau, and neurofibromatosis type 1.
• Familial paraganglioma-phaeochromocytoma syndromes, though less recognized, are increasingly identified through genetic testing.

Purpose of the Study:

• To elucidate the genetic basis of familial paraganglioma-phaeochromocytoma syndromes.
• To identify distinct genotypic-phenotypic correlations associated with succinate dehydrogenase (SDH) gene mutations.
• To understand the clinical presentation and metastatic potential of tumors based on specific SDH mutations.

Main Methods:

• Genetic analysis of succinate dehydrogenase (SDH) gene subunits (SDHD, SDHC, SDHB).
• Correlation of specific SDH mutations with patient demographics, tumor characteristics, and family history.
• Analysis of tumor location (head and neck, abdomen, pelvis) and metastatic potential.

Main Results:

• Four types of familial paraganglioma-phaeochromocytoma syndromes are associated with SDH mutations (types 1-4).
• SDHB mutations: 33% family history, single tumors around age 30, extra-adrenal tumors (abdomen/pelvis), 20% phaeochromocytomas, high metastatic potential.
• SDHD/SDHC mutations: 66% family history, head and neck paragangliomas; SDHD patients present at 30 with multiple tumors, SDHC patients at 38 with single tumors.

Conclusions:

• Succinate dehydrogenase (SDH) gene mutations are a key cause of familial paraganglioma-phaeochromocytoma syndromes.
• Distinct genotypic-phenotypic correlations exist for SDHB, SDHC, and SDHD mutations, influencing tumor behavior and patient outcomes.
• Genetic testing for SDH mutations is crucial for diagnosing and managing these rare tumors, including sporadic cases.